Tocilizumab

(USAN, rINN)
Synonyms: Atlizumab; MRA; R-1569; Tocilizumabum. Immunoglobulin G1, anti-(human interleukin 6 receptor) (human-mouse monoclonal MRA heavy chain), disulfide with human-mouse monoclonal MRA
Cyrillic synonym: Тоцилизумаб.

💊 Chemical information

CAS — 375823-41-9.

💊 Profile

Antagonists to the interleukin-6 receptor block the actions of interleukin-6 and are under investigation for rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis, adult-onset Still’s disease, Crohn’s disease, and haemolytic anaemia. Tocilizumab is a recombinant monoclonal antibody that targets the interleukin-6 receptor and is used for the treatment of Castleman’s disease, a rare lymphoproliferative disorder. It is also used for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis.
1. Nishimoto N, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95: 56–61
2. Ito H, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 2004; 126: 989–96
3. Nishimoto N. Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 2005; 28: 221–30
4. Yokota S, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol 2005; 28: 231–8
5. Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther 2006; 8 (suppl 2): S4. Available at: http:// arthritis-research.com/content/8/S2/S4 (accessed 11/02/08
6. Maini RN, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817–29
7. Paul-Pletzer K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today 2006; 42: 559–76
8. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619–26. Correction. ibid.; 691
9. Kanda J, et al. Reversible cardiomyopathy associated with multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody. Int J Hematol 2007; 85: 207–11
10. Matsuyama M, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med 2007; 46: 771–4
11. Smolen JS, et al. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987–97
12. Yokota S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998–1006.

💊 Preparations

Proprietary Preparations

Jpn: Actemra.
Published May 08, 2019.